| 261 |
GPL5283 |
AFFY Human Phase3 v1.0 - C50 |
2,961,291 |
Affymetrix, Inc. |
2007-05-23 |
Affymetrix |
Homo sapiens
 |
GeneChip |
in situ oligonucleotide, AFFY Human Phase3 v1.0 - C50, |
| 262 |
GPL5282 |
AFFY Human Phase3 v1.0 - C49 |
3,025,867 |
Affymetrix, Inc. |
2007-05-23 |
Affymetrix |
Homo sapiens
 |
GeneChip |
in situ oligonucleotide, AFFY Human Phase3 v1.0 - C49, |
| 263 |
GPL5281 |
AFFY Human Phase3 v1.0 - C48 |
3,055,678 |
Affymetrix, Inc. |
2007-05-23 |
Affymetrix |
Homo sapiens
 |
GeneChip |
in situ oligonucleotide, AFFY Human Phase3 v1.0 - C48, |
| 264 |
GPL5280 |
AFFY Human Phase3 v1.0 - C47 |
2,977,677 |
Affymetrix, Inc. |
2007-05-23 |
Affymetrix |
Homo sapiens
 |
GeneChip |
in situ oligonucleotide, AFFY Human Phase3 v1.0 - C47, |
| 265 |
GPL5279 |
AFFY Human Phase3 v1.0 - C46 |
2,951,415 |
Affymetrix, Inc. |
2007-05-23 |
Affymetrix |
Homo sapiens
 |
GeneChip |
in situ oligonucleotide, AFFY Human Phase3 v1.0 - C46, |
| 266 |
GPL5278 |
AFFY Human Phase3 v1.0 - C45 |
3,631,683 |
Affymetrix, Inc. |
2007-05-23 |
Affymetrix |
Homo sapiens
 |
GeneChip |
in situ oligonucleotide, AFFY Human Phase3 v1.0 - C45, |
| 267 |
GPL5277 |
AFFY Human Phase3 v1.0 - C44 |
2,933,603 |
Affymetrix, Inc. |
2007-05-23 |
Affymetrix |
Homo sapiens
 |
GeneChip |
in situ oligonucleotide, AFFY Human Phase3 v1.0 - C44, |
| 268 |
GPL5276 |
AFFY Human Phase3 v1.0 - C43 |
2,965,191 |
Affymetrix, Inc. |
2007-05-23 |
Affymetrix |
Homo sapiens
 |
GeneChip |
in situ oligonucleotide, AFFY Human Phase3 v1.0 - C43, |
| 269 |
GPL5275 |
AFFY Human Phase3 v1.0 - C42 |
3,025,971 |
Affymetrix, Inc. |
2007-05-23 |
Affymetrix |
Homo sapiens
 |
GeneChip |
in situ oligonucleotide, AFFY Human Phase3 v1.0 - C42, |
| 270 |
GPL5274 |
AFFY Human Phase3 v1.0 - C41 |
3,030,992 |
Affymetrix, Inc. |
2007-05-23 |
Affymetrix |
Homo sapiens
 |
GeneChip |
in situ oligonucleotide, AFFY Human Phase3 v1.0 - C41, |
| 271 |
GPL5273 |
AFFY Human Phase3 v1.0 - C40 |
2,944,356 |
Affymetrix, Inc. |
2007-05-23 |
Affymetrix |
Homo sapiens
 |
GeneChip |
in situ oligonucleotide, AFFY Human Phase3 v1.0 - C40, |
| 272 |
GPL5272 |
AFFY Human Phase3 v1.0 - C39 |
3,016,006 |
Affymetrix, Inc. |
2007-05-23 |
Affymetrix |
Homo sapiens
 |
GeneChip |
in situ oligonucleotide, AFFY Human Phase3 v1.0 - C39, |
| 273 |
GPL5271 |
AFFY Human Phase3 v1.0 - C38 |
3,078,854 |
Affymetrix, Inc. |
2007-05-23 |
Affymetrix |
Homo sapiens
 |
GeneChip |
in situ oligonucleotide, AFFY Human Phase3 v1.0 - C38, |
| 274 |
GPL5270 |
AFFY Human Phase3 v1.0 - C37 |
2,947,383 |
Affymetrix, Inc. |
2007-05-23 |
Affymetrix |
Homo sapiens
 |
GeneChip |
in situ oligonucleotide, AFFY Human Phase3 v1.0 - C37, |
| 275 |
GPL5269 |
AFFY Human Phase3 v1.0 - C36 |
2,966,266 |
Affymetrix, Inc. |
2007-05-23 |
Affymetrix |
Homo sapiens
 |
GeneChip |
in situ oligonucleotide, AFFY Human Phase3 v1.0 - C36, |
| 276 |
GPL5268 |
AFFY Human Phase3 v1.0 - C35 |
3,391,105 |
Affymetrix, Inc. |
2007-05-23 |
Affymetrix |
Homo sapiens
 |
GeneChip |
in situ oligonucleotide, AFFY Human Phase3 v1.0 - C35, |
| 277 |
GPL5267 |
AFFY Human Phase3 v1.0 - C34 |
4,320,474 |
Affymetrix, Inc. |
2007-05-23 |
Affymetrix |
Homo sapiens
 |
GeneChip |
in situ oligonucleotide, AFFY Human Phase3 v1.0 - C34, |
| 278 |
GPL5266 |
AFFY Human Phase3 v1.0 - C33 |
2,966,376 |
Affymetrix, Inc. |
2007-05-23 |
Affymetrix |
Homo sapiens
 |
GeneChip |
in situ oligonucleotide, AFFY Human Phase3 v1.0 - C33, |
| 279 |
GPL5265 |
AFFY Human Phase3 v1.0 - C32 |
2,933,940 |
Affymetrix, Inc. |
2007-05-23 |
Affymetrix |
Homo sapiens
 |
GeneChip |
in situ oligonucleotide, AFFY Human Phase3 v1.0 - C32, |
| 280 |
GPL5264 |
AFFY Human Phase3 v1.0 - C31 |
3,538,846 |
Affymetrix, Inc. |
2007-05-23 |
Affymetrix |
Homo sapiens
 |
GeneChip |
in situ oligonucleotide, AFFY Human Phase3 v1.0 - C31, |
|